Latest Commercial Expansion News

Unith Ltd boosted its AI digital human platform with ISO/IEC 27001:2022 certification, launched new SDKs, and secured $2.75 million in fresh capital to fuel growth and commercial expansion.

HITIQ Limited has fortified its financial position through a $1.4 million placement and secured milestone-based Victorian Government funding, accelerating its manufacturing expansion and commercial growth in concussion management technology.

OncoSil Medical reported a 53% increase in unit sales and advanced key regulatory approvals, including FDA final review and TGA listing, positioning it for growth in pancreatic cancer treatment.

ReNerve Limited delivered its strongest sales quarter ever with $211,000 in revenue, boosted by new distribution deals in Asia-Pacific and a $5 million funding facility to underpin growth.

Adherium Limited has posted a fourth consecutive quarter of record remote patient monitoring revenue, driven by growing device activations and strong clinical evidence from the iCARE study, positioning the company for expanded value-based care contracts in the US.

Carnegie Clean Energy has made substantial progress on its ACHIEVE Programme, including module assembly and regulatory approvals for ocean deployment in Spain, supported by a $2.5 million private placement to fund commercial expansion.

InteliCare generated positive cash flow for the first time since listing in the June 2026 quarter, driven by accelerated deployments across aged care and retirement living sectors.

InteliCare has expanded its agreement with Hardi Aged Care by adding 84 beds at Blacktown and initiating a phased Nurse Call system deployment across six facilities, lifting contract value by 13%.

Lumos Diagnostics reported a 6% revenue increase to US$13.2 million for FY26, driven by an 875% surge in FebriDx® sales following a pivotal CLIA waiver. The company expanded U.S. adoption to 170+ healthcare sites and secured milestone payments exceeding US$6 million.

Echo IQ has locked in a strategic $20 million investment and US partnership with Pro Medicus, alongside a $110 million capital raise, positioning the company for accelerated commercial expansion of its AI-driven cardiovascular diagnostics in the US.

Firebrick Pharma expanded its patent portfolio with grants in Canada and New Zealand while achieving 43% sales growth in FY26 despite steady operating expenses. The company is advancing Nasodine's commercial rollout across Southeast Asia and the US.

EBR Systems has launched the WiSE Coupler in the US, a new accessory designed to improve the implantation of its wireless cardiac pacing electrode. The device has FDA clearance and was piloted in 10 procedures, marking another step in the company’s US commercial expansion.